Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

QIAGEN and Illumina Unveil New Solutions to Advance Liquid Biopsy and Next-Generation Sequencing

The Role of Biobanks in Advancing Precision Medicine

AstraZeneca and Daiichi Sankyo's Enhertu Secures Conditional Approval in China for HER2-Mutated NSCLC Treatment

SkylineDx Presents Breakthrough Data from Largest Melanoma Genomic Assay Trial at SMR Annual Meeting

Clario and PathAI Join Forces to Streamline GI Clinical Trials with Integrated Solutions

FDA Approves FoundationOne® Liquid CDx as Companion Diagnostic for Itovebi™ (inavolisib) to Identify Hormone Receptor-Positive, HER2-Negative Breast Cancer Patients with PIK3CA Mutation

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay for Identifying Gastric and GEJ Cancer Patients Receives CE Mark Approval

Tempest and Roche Partner to Advance Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Singapore to Expand MediShield Life Coverage for Precision Medicine and Strengthen Genetic Data Protections

Bayer and MOMA Therapeutics Partner to Advance Precision Oncology Therapies

DermTech's Non-Invasive Genomic Testing Shows Promise in Differentiating Melanoma from Atypical Moles

Velsera and Diagnostic Longwood Partner to Accelerate Precision Medicine in Spain and Portugal

Aurigene Oncology Reports Promising Phase 1 Results for India’s First CAR-T Cell Therapy in Multiple Myeloma

Agilus Diagnostics Launches Pharmacogenomics Testing Service to Revolutionize Personalized Medicine

Home
/
update
/
details

Myriad Genetics Partners with GSK to Enhance HRD Testing Accessibility Across Nine Nations

NextEdge Admin

12 Jun 2024

2 min 15 sec

Myriad Genetics, has entered into a collaboration with GSK to broaden access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. Through this partnership, a sponsored testing program employing Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is being introduced across several countries, including Argentina, Brazil, and the United Arab Emirates. These tests serve a critical role in identifying HRD status, equipping clinicians with valuable information to make personalized treatment decisions for individuals battling ovarian cancer.

The collaboration between Myriad Genetics and GSK aims to address the pressing need for accessible testing solutions in underserved markets, ensuring that patients, regardless of their geographic location, can benefit from advanced genetic insights. Patrick Burke, the Executive Vice President of Strategy and Innovation at Myriad Genetics, highlighted the significance of this collaboration in advancing healthcare equity and extending the reach of diagnostic solutions to support tailored patient care based on individual genomic profiles.

Myriad’s MyChoice Test stands out as the most comprehensive tumor test available, offering a detailed analysis of genomic alterations, including in genes such as BRCA1 and BRCA2, alongside the Genomic Instability Score (GIS) status determined through a proprietary algorithm. This depth of analysis enables healthcare professionals to identify patients who are more likely to respond to treatment with targeted therapies, thereby improving treatment outcomes and patient quality of life.